Cancer vaccine shows sustained improvement in survival rates
Drug Discovery World
JUNE 6, 2024
Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. months after initial treatment. The follow-up of the Phase IIb study took place 34.9 It showed that the 2.5-year compared to 55.6%
Let's personalize your content